Overview
Recognise ARDS as acute inflammatory hypoxaemic respiratory failure, treat its precipitant, and deliver lung-protective critical care with timely proning and ECMO referral when conventional support is failing.
ARDS follows injury to alveolar epithelium and pulmonary endothelium. Protein-rich fluid floods alveoli, surfactant is disrupted, dependent lung collapses and pulmonary vascular resistance rises. Only a small, uneven “baby lung” remains available for ventilation, so apparently ordinary tidal volumes can overdistend functioning units and compound injury through volutrauma, barotrauma, atelectrauma and biological inflammation.
Diagnosis requires a compatible acute syndrome, bilateral imaging abnormalities, impaired oxygenation on positive pressure, and evidence that hydrostatic oedema is not the main explanation. The label should stimulate a systematic cause search rather than end one: bacterial or viral pneumonia, aspiration, extra-pulmonary sepsis, transfusion reaction, pancreatitis, autoimmune haemorrhage and drug injury require different definitive treatment.
Support aims to minimise additional lung and organ injury while the cause resolves. Ventilator settings, PEEP, proning, neuromuscular blockade and ECMO referral are individual critical-care decisions. The ICS/FICM ARDS guideline remains a central UK source, while sepsis guidance was updated in 2025 and GPICS v3 in 2026. Verify the unit’s current protocol rather than applying static thresholds without context.